Clinical Research Directory
Browse clinical research sites, groups, and studies.
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
Sponsor: ACADIA Pharmaceuticals Inc.
Summary
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?
Official title: A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
153
Start Date
2025-11-14
Completion Date
2027-09
Last Updated
2026-03-12
Healthy Volunteers
No
Interventions
ACP-211
ACP-211 monotherapy
Placebo
Placebo control
Locations (12)
Inland Psychiatric Medical Group
Chino, California, United States
Mountain View Clinical Research
Denver, Colorado, United States
Sandhill Research, LLC/DBA Accel Research Sites
Largo, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
IPTB Clinical Research
Tampa, Florida, United States
Vitalix Clinical, Inc.
Worcester, Massachusetts, United States
Redbird Research LLC
Las Vegas, Nevada, United States
CenExel Hassman Research Institute, LLC
Marlton, New Jersey, United States
Integrative Clinical Trials LLC
Brooklyn, New York, United States
Neuro-Behavioral Clinical Research
North Canton, Ohio, United States
Dynamed Clinical Research LP d/b/a DM Clinical Research
Houston, Texas, United States
Olympus Clinical Research, LLC
Katy, Texas, United States